- Home
- LITM vs ANEB Comparison
LITM vs ANEB Comparison
Compare LITM & ANEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LITM | ANEB |
|---|---|---|
| Founded | 2018 | 2020 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.4M | 46.0M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LITM | ANEB |
|---|---|---|
| Price | $2.99 | $0.99 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 481.9K | 113.9K |
| Earning Date | 12-24-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.34 | $0.90 |
| 52 Week High | $22.75 | $3.42 |
Technical Indicators
Market Signals| Indicator | LITM | ANEB |
|---|---|---|
| Relative Strength Index (RSI) | 41.92 | 17.21 |
| Support Level | $3.38 | $1.14 |
| Resistance Level | $3.84 | $1.25 |
| Average True Range (ATR) | 0.35 | 0.20 |
| MACD | -0.04 | -0.13 |
| Stochastic Oscillator | 3.03 | 5.61 |
Price Performance
Historical ComparisonAbout LITM Snow Lake Resources Ltd.
Snow Lake Resources Ltd is a Canadian clean energy exploration company with a world-wide portfolio of clean energy mineral projects comprised of two uranium projects and two hard rock lithium projects. Its Projects include: The Black Lake Uranium Project, the Engo Valley Uranium Project, The Shatford Lake Project, and the Snow Lake Lithium Project.
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.